secwatch.observer — SEC 8-K summary
======================================

Issuer:     9 METERS BIOPHARMA, INC. (—)
CIK:        0001551986
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001551986-23-000047
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

9 Meters CEO resigns; interim CEO appointed; vurolenatide Phase 2 trial planned
-------------------------------------------------------------------------------

- CEO John Temperato resigns effective May 26, 2023; Bethany Sensenig (CFO) named interim CEO.
- Separation agreement includes 12 months base salary, pro-rated 2023 bonus, and 12 months equity vesting extension.
- Company revises vurolenatide plan: additional Phase 2 trial for SBS instead of Phase 3, subject to funding availability.
- Company continues to assess strategic alternatives; trial timing depends on securing funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/0001551986-23-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551986/000155198623000047/nmtr-20230526.htm
  HTML page:      https://secwatch.observer/filing/0001551986-23-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer